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Abstract 
 
Background: To determine the association of thyroid 
disorders with chronic hepatitis C virus infection in 
patients who are not getting any antiviral treatment. 
Methods: Fifty patients without pre-existing thyroid 
abnormality having positive Hepatitis C Virus (HCV) 
infection (confirmed on PCR) and not willing for getting 
anti-viral treatment (interferon) were included in the 
study. Blood samples from 50 patients were collected at 
base line, 03 months, 06 months, 09 months and at 12 
months. The level of thyroid stimulating hormone (TSH) 
and thyroid antibodies was measured in these samples.  
Results: Eleven patients (22%) developed thyroid 
disorder during the study period. Majority of the patients 
(73%) developed thyroid disorder on the basis of change in 
TSH level whereas 18% developed thyroid disorder on the 
basis of alteration in thyroid antibodies levels and 9% 
patients abnormality both in TSH levels and change in 
thyroid antibody titre. 
Conclusion: A close association of thyroid disorder and 
chronic HCV infection is noted in the study population.  
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Introduction 
 
Hepatitis C, discovered in 1988, is one of the 
important causes of chronic liver disease1. It possesses 
six genotypes with more than 50 subtypes so far 
known. The viral genotypes have epidemiological 
clinical and therapeutic significance2. It has a frequent 
association of hepatocellular cancer3. A broad 
spectrum of extrahepatic syndromes has been 
observed in chronic hepatitis C. Autoimmune 
manifestation ranges from non-organ-specific 
autoantibody seropositivity and cryoglobulins to 
immunological diseases such as glomerulonephritis, 
vasculitis, lichen planus, and mixed 
cryoglobulinemia4-7. As a secondary event, 
autoreactivity is detected in liver disorders associated 
with a variety of etiological factors (e.g. drug- and 
chemical-induced autoimmunity, viral and microbial 
infection-induced autoimmunity)8,9. The combination 
of hepatitis C virus (HCV) infection and thyroid 
diseases raises several issues that are the prevalence of 
thyroid autoimmunity in patients with chronic 
hepatitis C, the prevalence of HCV infection in 
patients with autoimmune thyroid diseases, and the 
effects of interferon alpha treatment on thyroid 
function in chronic HCV hepatitis. The prevalence of 
anti-thyroid auto-antibodies ranges from 4.6 to 15% in 
HCV infection, which is considered as significant by 
various authors10.  
The association of thyroid dysfunction with 
HCV infected patients, who are on interferon therapy, 
is well established. But thyroid dysfunction in HCV 
patients, who are not receiving interferon therapy and 
not having pre- existing thyroid abnormalities is an 
aspect which the present study intended to explore..  
 
Patients and Methods  
 
It was a cross sectional observational study 
Inclusion Criteria: Diagnosed cases of HCV infection, 
who were not willing to get anti-HCV treatment 
(interferon). HCV positivity was defined as 
persistently raised serum aminotransferase (ALT) level 
associated with confirmation of positive anti HCV 
RNA antibody on PCR. 
Exclusion Criteria: Patients with pre-existing thyroid 
abnormality. Patients who started treatment during 
follow up period and patients with advanced liver 
disease 
A total of 50 patients were included in the 
study. The follow up of the patients was carried out 
for one year after every three months.  
Investigations:  
The following investigations were carried out 
in all patients at baseline i.e. at the time of induction in 
study and in their quarterly follow up visits till one 
year i.e. at 3, 6, 9 and 12 months.  
Thyroid Stimulating Hormone (TSH:The estimation of 
TSH was carried out on Immulite using 
chemiluminescence technique. The normal limits are 
between 0.4 to 4.0 IU/ml. The readings between this 
range were  considered as normal and any value 
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above or below this range  abnormal and labeled as 
high or low TSH value. If TSH value was above the 
normal range, no thyroxine replacement was given 
except when the level of TSH was above 8.5 IU/ml or 
there were gross clinical symptoms.  
Autoantibodies:Sera were investigated for the 
presence of thyroid microsomal antibodies. For 
autoantibody detection, standard indirect 
immunofluorescence tests on unfixed 4 µm cryostate 
sections from a composite block of mouse as well as 
from hyperplastic human (blood group 0) thyroid 
gland were used. The sera were diluted 1:10 and 1:100.  
Criteria of thyroid abnormality 
The following points were used to label a 
patient that he/she is developing thyroid abnormality 
during the follow up period of the study. 
(i)Alteration in TSH level beyond its normal 
limits either low or high 
(ii)Positive thyroid antibodies 
Statistical analysis  
The mean TSH levels were calculated at each 
follow up visit. The frequency and percentages of 
different thyroid abnormalities was calculated. The 
statistical analysis (χ2 test) was performed to 
determine the significant difference in number of male 
and female patient population as well as gender 
difference in development of thyroid abnormality. 
P<0.05 was considered statistically significant. 
 
Results  
 
The mean age of the study population was 
37.2 ± 1.09 years. The number of male patients was 31 
with a mean age of 37.6 ± 1.40 years. The female 
patients were 19 with mean age of 36.3 ± 1.68 years.  
According to the criteria defined, 11 patients 
(22%) developed thyroid abnormalities during the 
study period.  Out of these 11 patients, 73% showed 
abnormality in TSH levels, 18% developed positive 
thyroid antibody and 9% showed change in both TSH 
levels and positive thyroid antibody.  
The baseline mean TSH level of the study 
population was 4.17 ± 0.38 µIU/ml. During follow up 
period, eight patients showed change in TSH levels 
beyond normal limits. Out of these, 7 developed 
hypothyroidism and 1 hyperthyroidism. The patients 
who developed hypothyroidism were treated with 
oral thyroxine tablets and TSH level reverted to 
normal within three months in all patients (Table 1). 
Considering the gender difference, out of 11 
patients, 45% were females and 55% were males. 
Among females, 3 patients developed rise in TSH 
level, and 2 developed positive thyroid antibody 
during study period. Whereas in males, 4 patients, had 
raised TSH level, one developed hyperthyroidism and 
one male patient showed changes both in TSH level 
and positive thyroid antibody. 
Table 1: Patients developing thyroid 
abnormalities at quarterly follow up 
 Baseline 03 months 
06 
months 
09 
months 
12 
months 
No. of patients 50     
Mean TSH 
level 4.17±0.38 3.91±0.38 3.78±0.34 3.61±0.21 3.07±0.33 
Hypothyroid - 1 3 2 1 
Hyperthyroid - - - 1 - 
Positive 
thyroid 
antibody 
- 1 2 - - 
 
No significant difference was observed in the 
development of thyroid abnormalities on the basis of 
gender (male vs females; p=0.122). 
 
Discussion  
 
The criteria laid down in our study for 
positive thyroid disorder was either a positive thyroid 
antibody and/or a change (raised or low) in TSH value 
(normal value 0.4 to 4.0 µIU/ml). . About 22% of the 
study population showed development of thyroid 
disorders during the study period. These results are 
well matched with those already mentioned in the 
literature11,13.  
The most frequent clinical manifestation was 
hypothyroidism (Table 1). The patients, who 
developed hypothyroidism (High TSH) were not given 
specific treatment until the appearance of clinical 
symptoms. 
 The number of male patients in the present 
study was significantly higher than the female patients 
(p=0.029). The same was found in the study of Dalgard 
et al  (male patients 60%; n=153 vs. female patients 
40%; n=101) and Tran et al14  (male patients 55%; n=150 
vs. female patients 45%; n=122) 13 . 
The results of this study corroborate with the 
findings of Antonelli et al and Ploix et al ,  who 
observed that both hypothyroidism and thyroid 
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autoimmunity are more common in patients with 
chronic hepatitis C even in the absence of interferon 
treatment 11,12. 
In present study , no gender difference was 
observed in the development of thyroid abnormalities. 
  This observation differs from the findings of 
Prummel et al15, who explained that whatever the 
underlying pathophysiologic process , the major factor 
contributing to hypothyroidism includes the female 
gender with a relative risk ranging between 3-7 times 
and the presence of anti TPO antibodies. Moreover, 
Hsieh et al concluded in their study that female gender 
is a predisposing factor for development of thyroid 
abnormality in patients with HCV infection and 
getting α-interferon treatment 16.   
In the present study viral genotypes were not 
considered for the patients. Several studies in this field 
have shown that the serological pattern of 
autoantibodies does not correlate with a particular 
genotype of HCV11, 17   
The clinical significance of the serological 
markers of autoimmunity is still an object of 
discussion. But it seems that there are no significant 
differences in clinical and biochemical parameters 
between chronic hepatitis C patients with and without 
autoimmune features11,18. A recent study on the 
general population showed that in the absence of 
active liver disease the prevalence of non-organ 
specific auto antibodies was similar in HCV positive 
individuals and negative controls18. 
.  
Conclusion 
 
Thyroid abnormalities can develop in HCV 
patients without pre-existing thyroid abnormality 
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